Persistent effect of zoledronic acid in Paget's disease

Clinical and Experimental Rheumatology

Volumn 25, Issue 3, 2007, Pages 464-466

  Tziomalos, Konstantinos ^a,b   Florentin, Matilda ^a   Krikis, Napoleon ^a   Perifanis, Vassilios ^a   Karagiannis, Asterios ^a   Harsoulis, Faidon ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b NONE   (Greece)

Author keywords

Alkaline phosphatase; Bisphosphonates; Paget's bone disease; Sustained remission; Zoledronic acid

Indexed keywords

ALKALINE PHOSPHATASE; ZOLEDRONIC ACID;

ABSENCE OF SIDE EFFECTS; ADULT; ANAMNESIS; ARTICLE; BONE LESION; CASE REPORT; DRUG EFFICACY; FOLLOW UP; HIP RADIOGRAPHY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY COLIC; LABORATORY TEST; MALE; NEPHROLITHIASIS; OSTEOBLAST; OSTEOCLAST; OUTCOME ASSESSMENT; PAGET BONE DISEASE; PELVIS RADIOGRAPHY; PRIORITY JOURNAL; SINGLE DRUG DOSE; SPINE RADIOGRAPHY;

ALKALINE PHOSPHATASE; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; HUMANS; IMIDAZOLES; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; OSTEITIS DEFORMANS; OSTEOCLASTS; REMISSION INDUCTION;

EID: 34447650436     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. DELMAS PD, MEUNIER PJ: The management of Paget's disease of bone. N Engl J Med 1997; 336: 558-66.
2. NOOR M, SHOBACK D: Daget's disease of bone: diagnosis and treatment update. Curr Rheumatol Rep 2000; 2: 67-73.
3. FRASER WD: Paget's disease of bone. Curr Opin Rheumatol 1997; 9: 347-54.
4. REDDY SV, KURIHARA A, MENAA C, ROODMAN GD: Paget's disease of bone: a disease of the osteoclast. Rev Endocr Metab Disord 2001; 2: 195-201.
5. SIRIS ES: Paget's disease of bone. J Bone Miner Res 1998; 13: 1061-5.
6. TIEGS RD: Paget's dIsease of bone: indications for treatment and goals of therapy. Clin Ther 1997; 19: 1309-29.
7. GATTI D, ADAMI S: New bisphosphonates in the treatment of bone diseases. Drugs Aging 1999; 15: 285-96.
8. OADES GM, SENARATNE SG, CLARKE IA, KIRBY RS, COLSTON KW: Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells. J Urol 2003; 170: 246-52.
9. WIDLER L, JAEGGI KA, GLATT M et al.: Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa). J Med Chem 2002; 45: 3721-38.
10. SIRIS ES: Goals of treatment for Paget's disease of bone. J Bone Miner Res 1999; 14 Suppl. 2: 49-52.
11. MEUNIER PJ, SALSON C, MATHIEU L et al.: Skeletal distribution and biochemical parameters of Paget's disease. Clin Orthop Relat Res 1987; 217: 37-44.
12. RANDALL AG, KENT GN, GARCIA-WEBB P et al.: Comparison of biochemical markers of bone remover in Paget disease treated with pamidronate and a proposed model for the relationships between measurements of the different forms of pyridinoline cross-links. J Bone Miner Res 1996; 11: 1176-84.
13. WOITGE HW, OBERWITTLER H, HEICHEL S, GRAUER A, ZIEGLER R, SEIBEL MJ: Short- and long-term effects of ibandronate treatment on bone turnover in Paget disease of bone. Clin Chem 2000; 46: 684-90.
14. CACACE E, RUGGIERO V, MATULLI C, URAS L, PERPIGNANO G: Markers of bone resorption in bisphosphonate therapy of Paget's disease. Clin Exp Rheumatol 2004; 22: 502.
15. REINHOLZ GG, GETZ B, PEDERSON L et al.; Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. Cancer Res 2000; 60: 6001-7.
16. REID IR, MILLER P, LYLES K et al.: Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med 2005; 353: 898-908.